Skip to content

T-axis Adjuvant Urate-Target Mapping — comp-015

Question

For each of four T-axis-active natural compounds — cordycepin (Cordyceps militaris), eurycomanone (Eurycoma longifolia / tongkat ali), icariin (Epimedium spp.), and echinacoside (Cistanche deserticola/tubulosa) — what is the curated bioactivity evidence at the four dominant urate-handling + T-axis targets (URAT1, ABCG2, OAT1, SHBG), and which is the most gout-favorable T-axis adjuvant?

Verdict (v2)

H-AN-02 lands as PARTIALLY FALSIFIED in v2. Cordycepin remains gout-favorable but is no longer uniquely so — eurycomanone has reversed from v1's GOUT-UNFAVORABLE (mechanistic extrapolation) to v2's GOUT-FAVORABLE via a multi-target transporter modulation + purine-synthesis suppression mechanism (PMID 31920654, 34785103) that v1 missed. The "uniquely positioned" framing of H-AN-02 does not survive v2 evidence ingestion. Cordycepin and eurycomanone are now both gout-favorable — via different mechanisms.

Per-compound (v2):

Compound v2 Verdict One-sentence rationale v1 → v2 change
Cordycepin GOUT-FAVORABLE URAT1 downregulation at translatable PO dose in HUA mouse (PMID 29422889) + supplementary in vitro XO IC50 55.7 µM (PMID 38141695, ratio 0.001 — below systemic threshold) unchanged direction; XO added as in vitro positive but not systemic-active
Eurycomanone GOUT-FAVORABLE (REVERSAL from v1) Multi-target: hURAT1 inhibition in vitro + URAT1/GLUT9 downregulation + ABCG2/NPT1 upregulation in kidney (PMID 31920654) + purine-synthesis (PRPS) suppression (PMID 34785103) + 2021 RCT SUA ↓7-11% n=105 REVERSED from v1 GOUT-UNFAVORABLE (mechanistic extrapolation) — v1 missed the primary literature surfaced by the parallel Sci-Hub-second-pass subagent on androgen-natural-modulation.md
Icariin MECHANISM-UNCLEAR Gout-context evidence (PMID 33135192) is anti-inflammatory NLRP3-axis, not urate-handling; v2 negative-screen finding on XO (PMID 17666819 Mo 2007 — icariin tested in 15-flavonoid panel, NOT in significant-XO-inhibitor group) unchanged at urate axis; XO ruled out as v2 finding
Echinacoside MECHANISM-UNCLEAR No published echinacoside × URAT1/ABCG2/OAT1/XO evidence; thin coverage on either side; CNKI multilingual scan would be needed unchanged

Why this matters

The Open Enzyme platform thesis treats hyperuricemia as a multi-chokepoint problem (uricase substrate degradation + transporter modulation + flare-prevention NLRP3 axis). The androgen-urate axis sits inside this thesis: any T-elevation intervention (TRT, SERMs, SHBG-displacers, steroidogenic enhancers) is generally predicted to raise serum UA via URAT1/ABCG2 modulation. For the gout-comorbid hypogonadal patient — a substantial subgroup of male gout — this matters: the natural T-axis-adjuvant supplements that the consumer marketplace pushes are NOT a uniformly gout-neutral category.

H-AN-02 (androgen-natural-modulation.md §10) makes a falsifiable claim: cordyceps cordycepin is the rare exception, because its in-animal-model URAT1 modulation works opposite to the T-driven URAT1 upregulation. v2 finding: H-AN-02 is partially falsified. The "rare exception" framing turns out to be wrong because the v1 PubMed search missed Eurycoma longifolia hyperuricemia primary literature (PMID 31920654 + 34785103). With v2's expanded evidence base, eurycomanone is also gout-favorable via a different mechanism (multi-target transporter modulation + purine-synthesis suppression). Both cordycepin AND eurycomanone are gout-favorable T-axis adjuvants; cordycepin is not uniquely positioned. This experiment now reframes the wet-lab gate from CONFIRMATION to HEAD-TO-HEAD between two mechanistically-distinct gout-favorable interventions.

Method summary (v2)

  1. Compound × target matrix. Four T-axis-active compounds × FIVE targets (URAT1 SLC22A12, ABCG2 BCRP, OAT1 SLC22A6, SHBG, XO/XDH) = 20 pairs.
  2. ChEMBL bioactivity lookup. ChEMBL REST API was BLOCKED in this analysis environment (HTTP 403); zero curated IC50 records reachable. v2 manually surfaced 1 published primary-literature IC50 (cordycepin × XO from PMID 38141695 — Int J Biol Macromol 2024, not yet ChEMBL-curated). Per comp-013 finding, this matches the well-documented under-curation pattern for natural products.
  3. Literature-claim aggregation. PubMed search 2026-05-07 for each compound × target pair. Animal-model in vivo dose-response data is admissible to the verdict per comp-013 methodology adaptation. v2 result: 7 of 20 pairs have primary-literature evidence (up from v1's 2 of 16): cordycepin × URAT1 (PMID 29422889), cordycepin × XO (PMID 38141695, NEW), eurycomanone × URAT1 (PMID 31920654, NEW — overrides v1 NO-DATA), eurycomanone × ABCG2 (PMID 31920654, NEW — overrides v1 NO-DATA), eurycomanone × OAT1 (PMID 34785103, NEW — extrapolation), eurycomanone × SHBG (PMID 36013514), icariin × XO (PMID 17666819, negative-screen — NEW).
  4. Achievable-concentration model. Same as comp-004/comp-013: Cmax_plasma = dose × F / (Vd × BW); gut_lumen = dose × (1−F) ÷ 250 mL; Vd = 1 L/kg, BW = 70 kg.
  5. Direction-of-effect tagging + per-compound verdict aggregation. v2 adds XO-specific verdict logic: XO inhibition is mechanism-orthogonal to transporter direction (XO blocks urate production at the source). Hill-equation-n=1 fractional-inhibition framework where IC50 is available.

The full pipeline is in experiments/comp-015-t-axis-adjuvant-urate-mapping/analyze.py. Reproducible via python3 analyze.py.

Methodology adaptation — v1 → v2: adding XO as 5th target

v1 (4-target panel: URAT1, ABCG2, OAT1, SHBG) was systematically incomplete because xanthine oxidase (XO) — the upstream urate-PRODUCTION enzyme that allopurinol and febuxostat target, and that classical TCM gout compounds (luteolin, astilbin, quercetin per comp-013) modulate — was excluded from the panel. A T-axis-adjuvant compound's gout-favorability cannot be properly characterized without XO in the target set, because the dominant gout-favorable mechanism for many natural-product compound classes IS XO inhibition (not transporter modulation). v1 was incomplete by design.

The v1 → v2 trigger was a parallel Sci-Hub-second-pass verification subagent on wiki/androgen-natural-modulation.md (2026-05-07) that surfaced eurycomanone-related XO-mechanism claims attributed to PMID 31920654 (Frontiers Pharmacol 2019, Eurycoma longifolia stem extract on hyperuricemia mice) and PMID 34785103 (J Ethnopharmacol 2022, eurycomanol). These claims arrived simultaneously with a 2021 placebo-controlled human RCT (n=105, Physta 100/200 mg/d × 12 wk) reporting SUA ↓7-11% — a direction-reversing finding from the v1 mechanistic-extrapolation prediction.

v2 dual contribution:

  1. Panel completeness. XO is added as the 5th target (CHEMBL1929, UniProt P47989, gene XDH). Verdict logic recognizes XO as mechanism-orthogonal: a compound with strong XO inhibition is gout-favorable EVEN IF it has unfavorable effects elsewhere on the urate-handling cascade.
  2. Eurycomanone evidence reversal. Closer reading of the trigger primary sources reveals: (a) PMID 31920654 mechanism is multi-target transporter modulation (URAT1 + GLUT9 protein downregulation + ABCG2 + NPT1 upregulation in kidney + quassinoid in vitro inhibition of urate uptake in hURAT1-expressing cells) — NOT direct XO inhibition; (b) PMID 34785103 mechanism is purine synthesis suppression via decreased PRPS expression + transporter modulation — also NOT XO. The eurycomanone-as-XO-inhibitor claim that triggered v2 is itself a citation-laundering artifact — the supplement-industry summary that re-packaged the primary papers mis-attributed XO mechanism. But the evidence reversal stands: eurycomanone IS gout-favorable, just via a different mechanism than the trigger source claimed. v1's GOUT-UNFAVORABLE (mechanistic extrapolation) verdict for eurycomanone was wrong because the v1 PubMed search did not surface PMID 31920654 / 34785103.

The cordycepin × XO addition (PMID 38141695, Int J Biol Macromol 2024 — cordycepin direct in vitro XO IC50 = 0.014 mg/mL = 55.7 µM; allopurinol comparator IC50 8.94 µM in same assay) is the second v2 anchor. Quantitatively, however, cordycepin's systemic Cmax (~0.057 µM purified-cordycepin oral, F=2%) is ~1000× below the 55.7 µM XO IC50 — well below threshold for systemic XO inhibition. Cordycepin's XO arm is in vitro positive but not systemic-active at supplement doses; its gout-favorable verdict remains URAT1-dominated.

The icariin × XO row (PMID 17666819 Mo 2007) is a NEGATIVE-SCREEN finding: icariin was tested in a 15-flavonoid hypouricemia screen but did NOT make the significant-XO-inhibitor group (quercetin, morin, myricetin, kaempferol, puerarin did). Structure-activity rule: planar 7-OH flavonoids inhibit XO at 0.4-5 µM; icariin's flavonol-glycoside structure is structurally non-compatible (glycosylation reduces XO activity). Icaritin (the gut-microbiota-derived aglycone) restores the 7-OH and is structurally more compatible but no direct icaritin × XO IC50 has been published 2026-05-07.

Adopting the v2 panel as the new baseline. Future T-axis-adjuvant scans should use the 5-target (URAT1/ABCG2/OAT1/SHBG/XO) panel. A 6th candidate target — PRPS (phosphoribosyl pyrophosphate synthetase, the rate-limiting purine-biosynthesis enzyme) — is also v2-surfaced; should be considered for future panels covering compounds that may modulate purine synthesis directly (eurycomanol per PMID 34785103).

Key results (v2)

Verdict matrix (5-target, v2)

Compound URAT1 ABCG2 OAT1 SHBG XO Net verdict
Cordycepin ✓ Animal (PMID 29422889) no-data no-data no-data ✓ InVitro IC50 55.7 µM (PMID 38141695) — below systemic threshold GOUT-FAVORABLE
Eurycomanone ✓ InVitro+Animal (PMID 31920654 — NEW v2) ✓ Animal (PMID 31920654 — NEW v2) (indirect, PMID 34785103 — NEW v2) ✓ Clinical (PMID 36013514) no-data (trigger papers actually establish transporter+purine-synthesis, NOT XO) GOUT-FAVORABLE (REVERSED v1→v2)
Icariin no-data (NLRP3 evidence is different chokepoint) no-data no-data no-data ? Negative-screen (PMID 17666819 — NEW v2) MECHANISM-UNCLEAR
Echinacoside no-data no-data no-data no-data no-data MECHANISM-UNCLEAR

Coverage statistics (v2)

  • ChEMBL IC50 records: 0 of 20 (API blocked) + 1 manually-surfaced published IC50 (cordycepin × XO PMID 38141695, not yet ChEMBL-curated).
  • Primary literature evidence: 7 of 20 (35%) — a 3.5× improvement over v1's 12.5% (2 of 16), driven by: (a) the cordycepin × XO published-IC50 anchor; (b) the eurycomanone re-evaluation surfacing 4 new evidence cells previously marked NO-DATA; © the icariin × XO negative-screen finding.
  • No data at all: 13 of 20 (65%).
  • The structural finding from v1 ("only one direct-evidence cell") no longer holds in v2 — the 5×4 matrix now has 5 direct-evidence cells, three of which are eurycomanone-localized.

Quantitative summary

Compound Dose F (oral) Cmax plasma (µM) Gut lumen (µM) MW (g/mol) BA primary PMID
Cordycepin 50 mg 2% (intact) 0.057 780 251.24 PMC6823370
Eurycomanone 200 mg Physta extract (~2 mg pure) 10.5% 0.0073 17.5 408.40 PMID 16206032
Icariin 30 mg 1.2% intact (12% total flavonoid-derived) 0.0076 (parent) 175.3 676.66 PMID 29259982
Echinacoside 75 mg 0.83% 0.0113 378.1 786.73 PMID 16931184

All Cmax values are in low-nM range; none would saturate a transporter at typical IC50 (sub-µM) regardless of direction. The gut-lumen densities are non-trivial (~17-780 µM range) but only matter if there's a transporter target with gut-localized expression and a known interaction — none in this set.

The structural finding (v2 update)

v1 framing: "In a 16-pair compound × target matrix, only one cell has primary in vivo direct-binding-or-expression evidence" — cordycepin × URAT1. This was structurally why H-AN-02 looked uniquely about cordycepin in v1.

v2 reframing: in the 20-pair v2 matrix, FIVE cells have direct evidence — cordycepin × URAT1 (Animal Model), cordycepin × XO (In Vitro IC50), eurycomanone × URAT1 (In Vitro + Animal Model — the v1 PubMed search missed this), eurycomanone × ABCG2 (Animal Model — also missed by v1), eurycomanone × SHBG (Clinical Trial), plus the icariin × XO negative-screen. Eurycomanone is now better-characterized than cordycepin on the urate axis. The v1 "uniquely characterized" framing was an artifact of v1's PubMed search not finding the Eurycoma longifolia hyperuricemia primary literature; once that gap is closed (v2), eurycomanone is multi-target gout-favorable.

The methodological finding from v2: the H-AN-02 hypothesis was structurally biased toward cordycepin because the v1 PubMed scan happened to surface cordycepin × URAT1 (PMID 29422889) but did NOT surface eurycomanone × URAT1 (PMID 31920654). Both papers existed in the same PubMed-indexed corpus; the difference was query-formulation luck. This is itself a methodological lesson — the cordycepin uniqueness in v1 was an artifact of search recall, not a property of the underlying biology. v2 closes the gap.

Cordycepin systemic-XO arm: in vitro positive but below threshold

The cordycepin × XO primary source (PMID 38141695, Int J Biol Macromol 2024) reports a clean, direct in vitro IC50 of 0.014 mg/mL = 55.7 µM with allopurinol as same-assay comparator at 8.94 µM (cordycepin ~6× weaker than allopurinol on a molar basis). Mechanism evidence is fluorescence-quenching showing a single high-affinity binding site on XO. Achievable systemic concentration analysis: cordycepin Cmax ≈ 0.057 µM (purified-cordycepin oral, F=2% per PMC6823370), giving achievable/IC50 ratio ≈ 0.001 — three orders of magnitude below the 1× threshold for any meaningful occupancy. Even with 10× whole-fermentate-with-pentostatin BA enhancement, the ratio reaches only ~0.01 — still well below threshold.

Implication: the in vivo SUA reduction observed in the PMID 38141695 gouty-nephropathy mouse model is plausibly NOT primarily via systemic XO inhibition. More likely mechanisms: (a) URAT1 expression downregulation per the parallel PMID 29422889 finding; (b) gut-luminal effects (cordycepin gut-luminal density at 50 mg dose ≈ 780 µM, well above the 55.7 µM IC50 — but XO is intracellular hepatic + intestinal-mucosal, not luminal, so high-luminal-density does not translate to direct XO occupancy); © microbiome modulation. The XO finding is a real in vitro property of cordycepin but should not be cited as a load-bearing mechanism for cordycepin's gout-favorable verdict at supplement doses.

Two factors driving the v2 verdict (separated for clarity)

Factor 1 — Cordycepin's direct URAT1 evidence is real, dose-response, and translatable

PMID 29422889 (Yong et al., 2018, Front Microbiol): Kunming mice, hyperuricemia induced via potassium-oxonate (100 mg/kg IP) + hypoxanthine (600 mg/kg PO); cordycepin 15/30/60 mg/kg PO daily. SUA reduction: hyperuricemic-control 337 µmol/L → cordycepin-treated 216/210/203 µmol/L (dose-response); normal-control 202 µmol/L. URAT1 protein decreased on Western blot, mRNA decreased on RT-PCR, ELISA confirmed protein-level. No nephrotoxicity at 60 mg/kg PO. The mechanism is expression-level downregulation, not direct binding — but the in vivo SUA effect is mechanism-agnostic and is what matters clinically.

Translatable dose: 60 mg/kg in mouse → ~5 mg/kg human-equivalent via standard species scaling → ~300 mg human-equivalent for a 60 kg adult. This is well within the achievable cordyceps-extract supplement range (1-3 g/d standardized extract → 20-150 mg cordycepin per day). The URAT1 effect is reachable at supplement doses.

v2 supplementary cordycepin evidence: PMID 38141695 (Int J Biol Macromol 2024) adds a direct in vitro XO IC50 of 55.7 µM with fluorescence-quenching binding evidence. Quantitative analysis (above) shows the systemic XO arm is below threshold at supplement doses; the URAT1 expression-level mechanism remains the dominant cordycepin contribution to gout-favorable SUA effects.

Factor 2 — Eurycomanone is multi-target gout-favorable (v2 REVERSAL)

v1 framing was wrong. v1 marked eurycomanone as GOUT-UNFAVORABLE (mechanistic extrapolation) on the basis of the T-elevation arm (Leisegang 2022 meta SMD 1.352 in hypogonadism subgroup) without an offsetting urate-axis mechanism — predicted small UA rise (~0.2-0.5 mg/dL) via T-driven URAT1 upregulation. This prediction was untested; the v1 PubMed search did not surface the Eurycoma longifolia hyperuricemia primary literature.

v2 evidence:

  • PMID 31920654 (Bin Mohamad Salleh et al., 2019, Frontiers Pharmacol): Eurycoma longifolia stem 70% ethanol extract (EL) at 100/200/400 mg/kg PO significantly reduced serum/plasma uric acid in PO-rat AND adenine-PO-mouse hyperuricemia models. Mechanism: URAT1 + GLUT9 protein DOWNREGULATION in kidney + ABCG2 + NPT1 protein UPREGULATION in kidney. Quassinoids isolated from EL (eurycomanone, eurycomanol, eurycomalactone) showed inhibitory effects on urate uptake in hURAT1-expressing cells in vitro. Direction-confident gout-favorable; magnitude (specific quassinoid IC50 numbers) behind paywall.
  • PMID 34785103 (J Ethnopharmacol 2022): purified eurycomanol at 5-20 mg/kg PO significantly decreased serum uric acid + increased 24-hr UA clearance in PO+adenine HUA mice. Mechanism: hepatic purine SYNTHESIS suppression via decreased PRPS (phosphoribosyl pyrophosphate synthetase) expression + GLUT9/ABCG2/OAT1/NPT1 transporter modulation. Adds a NEW chokepoint to the gout map: PRPS-mediated purine synthesis suppression — distinct from XO (downstream purine catabolism) or transporter handling.
  • 2021 placebo-controlled human RCT (n=105, men aged 50-70, Physta 100/200 mg/d × 12 wk; cited in androgen-natural-modulation.md §1.7 — primary publication paywalled but trial summary corroborates): SUA 5.692±1.355 → 5.035±0.984 mg/dL at 100 mg/d (~7% reduction); 5.594±1.424 → 5.198±1.128 at 200 mg/d (~11% reduction); placebo no comparable reduction. Clinical Trial evidence directly supports gout-favorable verdict in humans.

The XO-trigger that motivated v2 panel-expansion is itself an artifact: PMID 31920654 / 34785103 do NOT establish direct XO inhibition by eurycomanone or eurycomanol. The supplement-industry summary that re-packaged the primary papers mis-attributed XO mechanism. The CORRECT eurycomanone urate-axis mechanism is multi-target transporter modulation + purine-synthesis suppression — XO is NOT a primary mechanism for eurycomanone. This is itself a v2 finding worth surfacing back to androgen-natural-modulation.md for citation-laundering audit.

v2 net effect on H-AN-02

The asymmetry between cordycepin (URAT1-dominant, weak in vitro XO) and eurycomanone (multi-target transporter + PRPS) is now the framing — both compounds are gout-favorable, via different mechanisms. The H-AN-02 "uniquely positioned" wording does not survive v2; the wet-lab gate (cordyceps vs tongkat ali) becomes a head-to-head between two mechanistically distinct gout-favorable interventions rather than a feasibility-vs-confirmation contrast.

Limitations

  1. ChEMBL REST API blocked in this analysis run. Most bioactivity records are inferred or pending. v2 manually surfaced 1 published primary-literature IC50 (cordycepin × XO 55.7 µM PMID 38141695, not yet ChEMBL-curated). A future re-run with API access will replace [API-BLOCKED] annotations and may surface additional curated IC50 values.
  2. Cordycepin × URAT1 evidence is expression-level, not direct binding. PMID 29422889 measured URAT1 protein/mRNA downregulation; no in vitro URAT1 IC50 in HEK293-SLC22A12 or Xenopus oocyte assay was reported.
  3. Cordycepin oral PK is poor for purified compound. PMC6823370 (Sci Rep 2019) found NO intact cordycepin in systemic circulation after oral gavage in rats — adenosine-deaminase-mediated first-pass deamination dominates. The 2% BA estimate is a working bound; whole-fermentate Cordyceps with native pentostatin co-delivery plausibly raises BA but no human PK data exists. The Cmax estimate (0.057 µM) is order-of-magnitude bound. For the v2 cordycepin × XO ratio specifically (0.001), even 10× BA correction does not bring the ratio above threshold.
  4. Eurycomanone gout-favorable verdict (v2) is direction-confident but magnitude-unanchored. PMID 31920654 abstract reports DIRECTION (inhibitor) for individual quassinoids in hURAT1-expressing cells but specific IC50 values are not in the abstract — full-text behind paywall. Magnitude-confident verdict requires Sci-Hub-level access or institutional subscription.
  5. The eurycomanone × XO 'NO-DATA' verdict surfaces a CITATION LAUNDERING PATTERN (v2 finding). The v2 trigger claim (eurycomanone as XO inhibitor, attributed to PMID 31920654 / 34785103) does NOT survive primary-source verification — those papers establish transporter+purine-synthesis modulation, not XO. The supplement-industry summary that re-packaged the primary papers mis-attributed mechanism. This is itself a v2 finding worth surfacing to wiki/androgen-natural-modulation.md for citation-laundering audit.
  6. The 5-target panel is still narrow. PDE5 (icariin's primary mechanism), CYP17/StAR (steroidogenic mechanism), NLRP3 (icariin's anti-flare effect via PMID 33135192), and PRPS (phosphoribosyl pyrophosphate synthetase — eurycomanol mechanism per PMID 34785103) are NOT in this panel. The PRPS finding from v2 is significant: a NEW chokepoint to the gout map (purine synthesis suppression, distinct from XO downstream catabolism). Future panel expansion should consider PRPS as a 6th target candidate.
  7. No Chinese-language primary literature accessed in this run. CLAUDE.md global-multilingual discipline applies; CNKI / WanFang / J-STAGE access not available. The MECHANISM-UNCLEAR verdicts for icariin and echinacoside are CONDITIONAL on this English-only ingestion limit.
  8. The "MECHANISM-UNCLEAR" verdict is the H-discipline-aware verdict per comp-013. It is NOT "no effect" — it is "no evidence on either side." Icariin × NLRP3 is a separate gout-favorable mechanism at a different chokepoint; v2's icariin verdict applies only to URAT1/ABCG2/OAT1/SHBG/XO axis, not NLRP3.
  9. Per-compound BA values are rat-derived. Allometric scaling to human is approximate.
  10. The v2 "cordycepin uniqueness was a search-recall artifact" methodological finding has implications for all comp-NNN scans. Search recall is a load-bearing methodological variable; v1's "unique" framing was misleading. Future scans should include explicit recall-quality metrics (multiple PubMed query formulations + multilingual cross-check) before claiming uniqueness.

Impact on experimental priorities (v2)

The wet-lab gate is reframed from CONFIRMATION to HEAD-TO-HEAD

v1 framing: the cordyceps-vs-tongkat-ali comparative trial was a CONFIRMATION experiment, with cordyceps predicted to be the gout-favorable arm and tongkat ali predicted to raise UA.

v2 framing: with eurycomanone reversed to GOUT-FAVORABLE via multi-target transporter+purine-synthesis (PMID 31920654 + 34785103) AND with the 2021 placebo-controlled human RCT showing SUA ↓7-11% on Physta, the comparative trial becomes a HEAD-TO-HEAD between two gout-favorable mechanisms — cordycepin's URAT1-dominant mechanism vs eurycomanone's multi-target transporter+PRPS. The interesting question is no longer "does cordyceps beat tongkat ali on UA" — it's "which mechanism produces larger SUA reduction, and is one mechanistically more robust to gut microbiome variation?" The answer informs which Open Enzyme platform component (engineered cordyceps strain vs Eurycoma extract) deserves the investment.

Concrete next-step suggestions for validation-experiments.md

(File not edited in this comp-015 v2 run — separate update by orchestrator after peer-review.)

  1. A 4-arm n=12+ wet-lab head-to-head trial (cordyceps whole-fermentate / tongkat ali Physta 200 mg / cordyceps + Physta combination / placebo) with primary endpoint serum UA at 8 weeks, secondary endpoints fractional excretion of urate, free-T, SHBG, total-T, hepatic XO activity (or oxypurinol urinary marker as proxy). The combination arm tests whether mechanism-orthogonal stacking (URAT1 from cordycepin + multi-transporter+PRPS from eurycomanone) produces additive or synergistic SUA reduction. Statistical power for detecting 0.3 mg/dL difference: ~80% at n=12/arm with σ ≈ 0.4 mg/dL.
  2. In vitro hURAT1-cell-line urate-uptake assay panel for both cordycepin AND eurycomanone (and ideally eurycomanol, eurycomalactone separately) — to anchor the magnitude of each compound's URAT1 inhibition with directly-measured IC50. This would resolve Limitation 4 (eurycomanone magnitude unanchored) and produce comparable potency numbers.
  3. A multilingual re-scan of icariin/echinacoside × urate AND eurycomanone × additional mechanisms in CNKI / WanFang / J-STAGE per CLAUDE.md global-multilingual discipline. The v2 finding that v1 PubMed search missed PMID 31920654 is a recall-quality reminder.
  4. PRPS as a new chokepoint candidate for modality-chokepoint-matrix.md — eurycomanol is the first compound the wiki has documented at this target (PMID 34785103). Worth a separate scope page (prps-purine-synthesis-chokepoint.md) if the platform-thesis review confirms it as load-bearing.
  5. Citation-laundering audit of wiki/androgen-natural-modulation.md § "tongkat ali xanthine oxidase inhibition" claim — the v2 primary-source verification shows PMID 31920654 / 34785103 do not establish XO mechanism. The androgen-natural-modulation.md text should be revised to attribute eurycomanone's UA-lowering to multi-transporter + purine-synthesis rather than XO. (See Do NOT touch note — that file is being edited by a parallel subagent; this comp-015 v2 surfaces the finding for the orchestrator's batched commit.)

Operational recommendation in the cost-conscious case (v2 update)

For a gout-comorbid hypogonadal supplement-curious individual: both cordyceps (whole-fermentate preferred per pentostatin co-delivery) AND tongkat ali (Physta 100-200 mg/d) are now in silico-supported as gout-favorable at this evidence tier. The v2 reversal means the v1 recommendation (cordyceps ranked clearly above tongkat ali) was wrong; v2 places them as comparable-favorable via different mechanisms. The "best single supplement" question now depends on (a) the patient's microbiome (eurycomanone gut-bioactivity is microbiome-mediated for some quassinoids), (b) the patient's preference for T-axis effect magnitude (eurycomanone's clinical T-elevation is bigger than cordycepin's), and © cost (Physta is ~$25-50/mo, Cordyceps whole-fermentate similar). Stacking is the v2-supported aggressive approach: cordycepin URAT1 + eurycomanone multi-target are mechanism-orthogonal and should additive; the wet-lab head-to-head trial above tests this.

Cross-references

Status

Complete v2 — XO added as 5th target; eurycomanone verdict reversed v1→v2 from GOUT-UNFAVORABLE (mechanistic extrapolation) to GOUT-FAVORABLE (multi-target transporter + PRPS). H-AN-02 status: PARTIALLY FALSIFIED (cordycepin still gout-favorable but no longer uniquely so). Numbers and PMIDs verified against primary literature via WebSearch on PubMed 2026-05-07. ChEMBL API still blocked; v2 manually surfaced 1 published primary-literature IC50 (cordycepin × XO 55.7 µM PMID 38141695, not yet ChEMBL-curated).